Exchange: NYSE·Updated 07:30 PM EDT

GKOS News

News
all
press releases
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
Zacks
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%. Currently, Glaukos has a market capitalization of $10.97 billion.read more...
Benzinga
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
Zacks
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
Zacks
Glaukos Announces Participation in Wells Fargo Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference...
Business Wire
Glaukos (GKOS) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.
Zacks
GKOS Crosses Above Average Analyst Target
In recent trading, shares of Glaukos Corp (Symbol: GKOS) have crossed above the average analyst 12-month target price of $164.50, changing hands for $168.52/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valua...
Nasdaq News: Markets

Advertisement|Remove ads.